Based on the available clinical trial data, pregnant women who received Pfizer’s ABRYSVO RSV vaccine were more likely to experience premature delivery of their infants when compared to those who received the placebo (5.6 percent versus 4.7 percent). Pregnant women also experienced higher rates of pre-eclampsia and gestational hypertension when compared to those who received the placebo.
In clinical trials, infants born to mothers who received ABRYSVO RSV vaccine had higher rates of low birth weight and jaundice when compared to the infants of mothers who received the placebo.
There is no safety data on the use of drug nirsevimab in infants whose mothers received RSV vaccine during pregnancy. To learn about nirsevimab, visit NVIC’s RSV Prevention and Treatment page.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Respiratory Syncytial Virus (RSV) and the Respiratory Syncytial Virus (RSV) vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
